Controlled Release of Drugs from Liposomes Using Ultrasound

This book presents an interdisciplinary study led by Dr. Yechezkel Barenholz, co-inventor of the FDA-approved liposomal drug - Doxil; Dr. Joseph Kost, a pioneer in the field of ultrasound-based drug delivery systems; and Dr. Avi Schroeder, a PhD-student of the two, whose doctoral research serves as the basis for this book.

Liposomes, vesicles with one or more lipid bilayers entrapping an inner aqueous core, are widely used as drug delivery systems. When liposomes are smaller than 100 nanometers (nano liposomes) they have a unique capability of selectively accumulating in tumors and inflamed tissues. This phenomenon, known as the enhanced permeability and retention (EPR) effect, is related to the relatively high leakiness' of blood vessels in these diseased tissues. In this book, we present a novel approach for triggering drug release from liposomes at the target site, by use of a remote trigger low frequency ultrasound. The book includes detailed descriptions of formulation, characterization, and in vivo performance of liposome-based drugs, with focus and insights into the biophysical phenomena governing ultrasound-induced liposomal drug release. Special attention is given to the principles needed to formulate ultrasound-responsive liposomes. The book is intended for people entering the field of liposome-based drug delivery as well as experienced scientists seeking fundamental understanding of the mechanism by which ultrasound interacts with lipid bilayers.